Just awful.
Respiratory sales falling (Dec 22 $6.15m; Jun '23 $5.56m; Dec '23 $5.52m) - which is interesting because over that period we were led to believe that US market pharmacy distribution had increased.
Penthrox sales well down on previous half (no NOT PC half, the June '23 half). If we can't hit double digit growth now its never going to happen.
Sounds like mgmt are back to dart throwing when it comes to market entry. I can't see why a partner approach will succeed when the direct approach to France failed so badly.
The comments on going forward without a partner on the non-clinical studies for US scream BIG cap raise ahead.
Love to hear from anyone who got some positives out of this report.
Ann: 2024 Half Year Announcement, page-2
Add MVP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.0¢ |
Change
-0.005(1.23%) |
Mkt cap ! $34.52M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 41.5¢ | 38.0¢ | $23.62K | 59.10K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 17669 | 40.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.5¢ | 3922 | 1 |
View Market Depth
| Last trade - 16.10pm 17/06/2024 (20 minute delay) ? |
|
|||||
|
Last
40.5¢ |
Change
-0.005 ( 2.95 %) |
||||
| Open | High | Low | Volume | ||
| 40.5¢ | 41.0¢ | 39.5¢ | 7430 | ||
| Last updated 15.59pm 17/06/2024 ? | |||||
| MVP (ASX) Chart |
